Uqba Khan, M.D. at NewYork-Presbyterian ...

Dr. Uqba Khan

Claim this profile

New York-Presbyterian/Brooklyn Methodist Hospital

Studies Colorectal Cancer
Studies Colon Cancer
5 reported clinical trials
17 drugs studied

Area of expertise

1Colorectal Cancer
Uqba Khan has run 2 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
dMMR negative
MSI-H negative
2Colon Cancer
Uqba Khan has run 2 trials for Colon Cancer. Some of their research focus areas include:
Stage IV
Stage III
MSS positive

Affiliated Hospitals

Image of trial facility.
New York-Presbyterian Brooklyn Methodist Hospital

Clinical Trials Uqba Khan is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Chemotherapy Tailored by ctDNA Status

for Colon Cancer

This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Recruiting1 award Phase 2 & 3

More about Uqba Khan

Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Uqba Khan has experience with
  • Irinotecan
  • MFOLFIRINOX
  • Bevacizumab
  • Leucovorin Calcium
  • Fluorouracil
  • Irinotecan Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Uqba Khan specialize in?
Is Uqba Khan currently recruiting for clinical trials?
Are there any treatments that Uqba Khan has studied deeply?
What is the best way to schedule an appointment with Uqba Khan?
What is the office address of Uqba Khan?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security